Finanzen von Bone Biologics Corp (BBLG)BBLGBone Biologics Corp

Evaluating the bottom line, Bone Biologics Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -47.49%, provide a clear picture of how effectively BBLG converts its operational activities into shareholder value.

In the context of the broader market, BBLG competes directly with industry leaders such as VBIO and VJET. With a market capitalization of $1.12M, it holds a significant position in the sector. When comparing efficiency, BBLG's gross margin of N/A stands against VBIO's N/A and VJET's 9.62%. Such benchmarking helps identify whether Bone Biologics Corp is trading at a premium or discount relative to its financial performance.

BBLG has shown continuous negative net income over the past quarters, with the latest reported loss of $617,651 in Q3 2026. The company has a forward P/E of 0, indicating no anticipated earnings growth, and a price-to-book ratio of 0.184, suggesting significant undervaluation but also potential financial distress.